Oral delivery of bi-autoantigens by bacterium-like particles (BLPs) against autoimmune diabetes in NOD mice

References

• Baidal DA, Warnock M, Xu P, et al. (2022). Oral glucose tolerance test measures of first-phase insulin response and their predictive ability for type 1 diabetes. J Clin Endocrinol Metab 107:1–13.
   PubMed Web of Science ®Google Scholar
• Bauer W, Gyenesei A, Kretowski A. (2021). The multifactorial progression from the islet autoimmunity to type 1 diabetes in children. Int J Mol Sci 22:7493.
   PubMed Web of Science ®Google Scholar
• Bluestone JA, Buckner JH, Herold KC. (2021). Immunotherapy: building a bridge to a cure for type 1 diabetes. Science 373:510–6.
   PubMed Web of Science ®Google Scholar
• Bluestone JA, Herold K, Eisenbarth G. (2010). Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature 464:1293–300.
   PubMed Web of Science ®Google Scholar
• Bonifacio E, Ziegler AG, Klingensmith G, et al. (2015). Effects of high-dose oral insulin on immune responses in children at high risk for type 1 diabetes: the Pre-POINT randomized clinical trial. Jama 313:1541–9.
   PubMed Web of Science ®Google Scholar
• Chen Y, Wu J, Wang J, et al. (2018). Targeted delivery of antigen to intestinal dendritic cells induces oral tolerance and prevents autoimmune diabetes in NOD mice. Diabetologia 61:1384–96.
   PubMed Web of Science ®Google Scholar
• Chwalba A, Pilśniak A, Otto-Buczkowska E. (2021). Beta-cell self-destruction and extremely complicated and still unknown etiopathogenesis of type 1 diabetes. Pediatr Endocrinol Diabetes Metab 27:47–50.
   PubMedGoogle Scholar
• Crane IJ, Forrester JV. (2005). Th1 and Th2 lymphocytes in autoimmune disease. Crit Rev Immunol 25:75–102.
   PubMed Web of Science ®Google Scholar
• Dayan CM, Besser REJ, Oram RA, et al. (2021). Preventing type 1 diabetes in childhood. Science 373:506–10.
   PubMed Web of Science ®Google Scholar
• Evans-Molina C, Sims EK, DiMeglio LA, et al. (2018). β Cell dysfunction exists more than 5 years before type 1 diabetes diagnosis. JCI Insight 3:e120877.
   PubMed Web of Science ®Google Scholar
• Felton JL. (2021). Timing of immunotherapy in type 1 diabetes: the earlier, the better? Immunohorizons 5:535–42.
   PubMedGoogle Scholar
• Gong Z, Pan L, Le Y, et al. (2010). Glutamic acid decarboxylase epitope protects against autoimmune diabetes through activation of Th2 immune response and induction of possible regulatory mechanism. Vaccine 28:4052–8.
   PubMed Web of Science ®Google Scholar
• Hadis U, Wahl B, Schulz O, et al. (2011). Intestinal tolerance requires gut homing and expansion of FoxP3+ regulatory T cells in the lamina propria. Immunity 34:237–46.
   PubMed Web of Science ®Google Scholar
• Kanta A, Lyka E, Koufakis T, et al. (2020). Prevention strategies for type 1 diabetes: a story of promising efforts and unmet expectations. Hormones (Athens) 19:453–65.
   PubMedGoogle Scholar
• Katsarou A, Gudbjornsdottir S, Rawshani A, et al. (2017). Type 1 diabetes mellitus. Nat Rev Dis Primers 3:17016.
   PubMed Web of Science ®Google Scholar
• Kazi TA, Acharya A, Mukhopadhyay BC, et al. (2022). Plasmid-based gene expression systems for lactic acid bacteria: a review. Microorganisms 10:1132.
   PubMed Web of Science ®Google Scholar
• Kreiner FF, von Scholten BJ, Coppieters K, von Herrath M. (2021). Current state of antigen-specific immunotherapy for type 1 diabetes. Curr Opin Endocrinol Diabetes Obes 28:411–8.
   PubMedGoogle Scholar
• Lampasona V, Liberati D. (2016). Islet autoantibodies. Curr Diab Rep 16:53.
   PubMed Web of Science ®Google Scholar
• Lang J, Wang X, Liu K, et al. (2017). Oral delivery of staphylococcal nuclease by Lactococcus lactis prevents type 1 diabetes mellitus in NOD mice. Appl Microbiol Biotechnol 101:7653–62.
   PubMed Web of Science ®Google Scholar
• Levit R, Cortes-Perez NG, de Moreno de Leblanc A, et al. (2022). Use of genetically modified lactic acid bacteria and bifidobacteria as live delivery vectors for human and animal health. Gut Microbes 14:2110821.
   PubMed Web of Science ®Google Scholar
• Liu B, Yue Y, Yang Y, Jin Y. (2016). Oral administration of silkworm-produced GAD65 and insulin Bi-autoantigens against type 1 diabetes. PLoS One 11:e0147260.
   PubMed Web of Science ®Google Scholar
• Mao R, Chen Y, Wu Q, et al. (2019). Oral delivery of single-chain insulin (SCI-59) analog by bacterium-like particles (BLPs) induces oral tolerance and prevents autoimmune diabetes in NOD mice. Immunol Lett 214:37–44.
   PubMed Web of Science ®Google Scholar
• Mao R, Wu D, Hu S, et al. (2017). Secretory expression and surface display of a new and biologically active single-chain insulin (SCI-59) analog by lactic acid bacteria. Appl Microbiol Biotechnol 101:3259–71.
   PubMed Web of Science ®Google Scholar
• Mao R, Wu D, Wang Y. (2016). Surface display on lactic acid bacteria without genetic modification: strategies and applications. Appl Microbiol Biotechnol 100:9407–21.
   PubMed Web of Science ®Google Scholar
• Mao R, Yang M, Yang R, et al. (2022). Oral delivery of the intracellular domain of the insulinoma-associated protein 2 (IA-2ic) by bacterium-like particles (BLPs) prevents type 1 diabetes mellitus in NOD mice. Drug Deliv 29:925–36.
   PubMed Web of Science ®Google Scholar
• Mao RF, Chen YY, Diao EJ, et al. (2020). Oral tolerance therapy in type 1 diabetes mellitus. Chin Med J (Engl) 134:44–6.
   PubMed Web of Science ®Google Scholar
• Mao RF, Chen YY, Zhang J, et al. (2020). Type 1 diabetes mellitus and its oral tolerance therapy. World J Diabetes 11:400–15.
   PubMed Web of Science ®Google Scholar
• Mastrandrea LD, Quattrin T. (2022). Preventing type 1 diabetes development and preserving beta-cell function. Curr Opin Endocrinol Diabetes Obes 29:386–91.
   PubMedGoogle Scholar
• Mitchell AM, Michels AW. (2022). Self-antigens targeted by regulatory T cells in type 1 diabetes. Int J Mol Sci 23:3155.
   PubMed Web of Science ®Google Scholar
• Patterson C, Guariguata L, Dahlquist G, et al. (2014). Diabetes in the young – a global view and worldwide estimates of numbers of children with type 1 diabetes. Diabetes Res Clin Pract 103:161–75.
   PubMed Web of Science ®Google Scholar
• Peakman M. (2013). Immunological pathways to beta-cell damage in type 1 diabetes. Diabet Med 30:147–54.
   PubMed Web of Science ®Google Scholar
• Pham MN, Gibson C, Rydén AK, et al. (2016). Oral insulin (human, murine, or porcine) does not prevent diabetes in the non-obese diabetic mouse. Clin Immunol 164:28–33.
   PubMed Web of Science ®Google Scholar
• Pinheiro-Rosa N, Torres L, Oliveira MA, et al. (2021). Oral tolerance as antigen-specific immunotherapy. Immunother Adv 1:ltab017.
   PubMedGoogle Scholar
• Rezende RM, Weiner HL. (2017). History and mechanisms of oral tolerance. Semin Immunol 30:3–11.
   PubMed Web of Science ®Google Scholar
• Rezende RM, Weiner HL. (2022). Oral tolerance: an updated review. Immunol Lett 245:29–37.
   PubMed Web of Science ®Google Scholar
• Richardson SJ, Pugliese A. (2021). 100 years of insulin: pancreas pathology in type 1 diabetes: an evolving story. J Endocrinol 252:R41–R57.
   PubMed Web of Science ®Google Scholar
• Ruterbusch M, Pruner KB, Shehata L, Pepper M. (2020). In vivo CD4(+) T cell differentiation and function: revisiting the Th1/Th2 paradigm. Annu Rev Immunol 38:705–25.
   PubMed Web of Science ®Google Scholar
• Saluja V, Visser MR, van Roosmalen ML, et al. (2010). Gastro-intestinal delivery of influenza subunit vaccine formulation adjuvanted with Gram-positive enhancer matrix (GEM) particles. Eur J Pharm Biopharm 76:470–4.
   PubMed Web of Science ®Google Scholar
• Serra P, Santamaria P. (2019). Antigen-specific therapeutic approaches for autoimmunity. Nat Biotechnol 37:238–51.
   PubMed Web of Science ®Google Scholar
• Siewko K, Popławska-Kita A, Telejko B, et al. (2014). Prognostic markers for the development of type 1 diabetes in first-degree relatives of diabetic patients. Endokrynol Pol 65:176–80.
   PubMed Web of Science ®Google Scholar
• Simmons KM, Michels AW. (2015). Type 1 diabetes: a predictable disease. World J Diabetes 6:380–90.
   PubMed Web of Science ®Google Scholar
• Smigoc Schweiger D. (2022). Recent advances in immune-based therapies for type 1 diabetes. Horm Res Paediatr. doi: 10.1159/000524866
   PubMed Web of Science ®Google Scholar
• Sricharunrat T, Pumirat P, Leaungwutiwong P. (2018). Oral tolerance: recent advances on mechanisms and potential applications. Asian Pac J Allergy Immunol 36:207–16.
   PubMed Web of Science ®Google Scholar
• Steen A, Buist G, Leenhouts KJ, et al. (2003). Cell wall attachment of a widely distributed peptidoglycan binding domain is hindered by cell wall constituents. J Biol Chem 278:23874–81.
   PubMed Web of Science ®Google Scholar
• Tordesillas L, Berin MC. (2018). Mechanisms of oral tolerance. Clin Rev Allergy Immunol 55:107–17.
   PubMed Web of Science ®Google Scholar
• Van Braeckel-Budimir N, Haijema BJ, Leenhouts K. (2013). Bacterium-like particles for efficient immune stimulation of existing vaccines and new subunit vaccines in mucosal applications. Front Immunol 4:282.
   PubMed Web of Science ®Google Scholar
• van Roosmalen ML, Kanninga R, El Khattabi M, et al. (2006). Mucosal vaccine delivery of antigens tightly bound to an adjuvant particle made from food-grade bacteria. Methods 38:144–9.
   PubMed Web of Science ®Google Scholar
• Wambre E, Jeong D. (2018). Oral tolerance development and maintenance. Immunol Allergy Clin North Am 38:27–37.
   PubMed Web of Science ®Google Scholar
• Wing K, Sakaguchi S. (2010). Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nat Immunol 11:7–13.
   PubMed Web of Science ®Google Scholar
• Zajec A, Podkrajsek KT, Tesovnik T, et al. (2022). Pathogenesis of type 1 diabetes: established facts and new insights. Genes (Basel)13:706.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhang Y, Gu W, Sun B. (2014). TH1/TH2 cell differentiation and molecular signals. Adv Exp Med Biol 841:15–44.
   PubMed Web of Science ®Google Scholar